Navigation Links
Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
Date:6/3/2009

COPENHAGEN, June 3 /PRNewswire/ -- Santaris Pharma and Copenhagen Institute of Technology, Aalborg University, Denmark, announced today that Director of microRNA, Santaris Pharma, Sakari Kauppinen, has been appointed Adjunct Professor in RNA Biology at Copenhagen Institute of Technology. The appointment has immediate effect and will last five years. Sakari Kauppinen, who will continue his in current role as Director of MicroRNA Research at Santaris Pharma, will give his inaugural lecture in August this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

Sakari Kauppinen, Director of MicroRNA Research at Santaris Pharma said:

"I feel very honored to be appointed Adjunct Professor in RNA Biology at the Copenhagen Institute of Technology, Aalborg University. Close collaborations with academia are essential for Santaris Pharma's expanding microRNA therapeutics program, which aims at translating the basic knowledge about microRNAs in disease into development of novel medicines with the potential to improve human health. I am looking forward to interacting closely with Aalborg University, whose experience in working with the biotech industry is highly synergistic with our way of collaborating with academia."

Soren Tulstrup, CEO of Santaris Pharma said:

"We are thrilled that Sakari Kauppinen has received this important academic appointment. Sakari Kauppinen has helped bring Santaris Pharma to a leadership position worldwide within the exciting new scientific field of microRNA, and I am sure he will contribute significantly to the university in his future additional capacity as Adjunct Professor."

Lene Lange, Professor, Dr. Scient. Vice Dean for the Faculties of Engineering, Science and Medicine, Aalborg University said:

"Sakari Kauppinen is superbly qualified for the position as Adjunct Professor at Copenhagen Institute of Technology, Aalborg University. The decision was made based upon his groundbreaking work, his standing as an international leader in the microRNA field, his service to the scientific community, and his status as a valued and generous colleague. A close relationship with the knowledge intensive private industry is very important to Aalborg University, so the fact that Sakari Kauppinen can achieve this stature while working as a scientist in Santaris Pharma makes him a truly rare individual and even more valuable for Copenhagen Institute of Technology and Aalborg University. The university is fortunate to have Sakari Kauppinen as a member of the Faculties of Engineering, Science and Medicine."

http://www.santaris.com

Santaris Pharma (founded in 2003) is a privately held biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and upfront payments.

    Contact

    For further information, please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com



'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
3. 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
4. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
5. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. ViroPharma to Present at Two June Healthcare Conferences
8. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. Pharmacyclics Files Registration Statement for Rights Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Amgen (NASDAQ: AMGN ) ... the submission of a Marketing Authorization Application (MAA) to the ... to Avastin ® (bevacizumab). The companies believe this submission ... "The submission of ABP 215 to the ... our oncology portfolio," said Sean E. Harper , M.D., ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes ... standardization and a beautiful technology experience. All three tenets were on display at the ... trial leaders from over 40 sponsor, CRO and site organizations to discuss innovation and ...
(Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... today that the Company has concluded an agreement with ... for a 90-day period to acquire units of the ... approximately USD 3.7 million.  Concurrently with ... Tamarack under which Tamarack will seek regulatory approvals in ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):